Allyson J. Ocean, Professor of Clinical Medicine at Weill Cornell Medicine, shared on LinkedIn:
“I’ve been treating #pancreaticcancer for more than 20 years, always hoping for moments like this.
Today, I wrote my first prescription for daraxonrasib.
It’s hard to describe what it feels like to finally prescribe a drug that targets RAS, something we once thought was ‘undruggable.’
I’m thinking about every patient who enrolled in a clinical trial, every patient we’ve lost, and every scientist and clinician who refused to give up.
For me, this isn’t just a new prescription. It’s a milestone I’ve been waiting my entire career to see.
Progress. Hope. And a new chapter for our patients.”
You may also be interested in: Daraxonrasib Opens a Broader RAS-Targeting Strategy in Previously Treated NSCLC
